Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease

Pharmacotherapy

Volumn 22, Issue 9 II, 2002, Pages

  Hudson, Joanna Q ^a   Sameri, Roya M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG HALF LIFE; GLOMERULUS FILTRATION RATE; HEADACHE; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; KIDNEY FAILURE; MYALGIA; NONHUMAN; QUALITY OF LIFE; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANEMIA; ANIMALS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC;

EID: 0036363545     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.14.141s.33397     Document Type: Review

References (48)

1. Chronic kidney disease
2. Serum creatinine levels in the U.S. population: Third national health and nutrition examination survey
3. Biology of erythropoietin
4. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin
5. Anemia: An early complication of chronic renal insufficiency
6. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States
7. Quality of life in predialytic uremic patients
8. Defining a renal anemia management period
9. Optimization of pre-ESRD care: The key to improved dialysis outcomes
10. Cardiac function and hematocrit level
11. How should anemia be managed in pre-dialysis patients?
12. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin: The cooperative multicenter erythropoietin clinical trial group
13. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
14. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients
15. Transfusion medicine. Part I. Blood transfusion
16. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis
17. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and phase II clinical trial
18. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000
19. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration
20. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients
21. The role of carbohydrate on the biological activity of erythropoietin
22. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO)
23. Rational design of novel erythropoiesis stimulating protein (Aranesp™): A super-sialylated molecule with increased biological activity
24. Novel erythropoiesis stimulating protein
25. Clinical pharmacology of recombinant human erythropoietin (r-HuEPO)
26. Development and characterization of novel erythropoiesis stimulating protein (NESP)
27. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis
28. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time- and dose-linear
29. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in pediatric patients with chronic renal failure (CRF) or end-stage renal disease
30. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency
31. Aranesp™ (darbepoetin alfa) administered once every other week (Q2W) corrects anemia in patients with chronic kidney disease
32. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin
33. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin
34. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients
35. Novel erythropoiesis stimulating protein (NESP) administered once every other week corrects anemia in patients with early chronic kidney disease
36. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia
37. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP)
38. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients
39. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once ever), other week: European/Australian NESP 970290 study group
40. Novel erythropoiesis stimulating protein (NESP) administered once ever), 3 weeks by the intravenous or subcutaneous route maintains hemoglobin (Hb) in dialysis patients: European/Australian NESP 2000-0144 study group
41. Aranesp™ (darbepoetin alfa) administered at a reduced frequency of once ever), 4 weeks (Q4W) maintains hemoglobin levels in patients with chronic kidney disease (CKD) receiving dialysis: European/Australian 200000144 study team
42. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients
43. HRQOL improvements in anemic CKD patients treated with darbepoetin alfa (Aranesp™)
44. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients
45. Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis
46. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?